Cargando…
ODP563 Breast Cancer With Liver Metastasis Responds Poorly to Fulvestrant-Based Combination Therapy and Chemotherapy
BACKGROUND: Estrogen receptor-positive (ER+) metastatic breast cancer (MBC) contributes to nearly 70% of breast cancer-related deaths. Liver metastasis is the third most common site and has been found to carry a poor prognosis. One contributing factor is resistance to available treatments. Meanwhile...
Autores principales: | Chien, Christine, Raghavendra, Akshara S, Tripathy, Debasish, Madak-Erdogan, Zeynep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627950/ http://dx.doi.org/10.1210/jendso/bvac150.1816 |
Ejemplares similares
-
ODP647 Nuclear ERα and NAMPT Crosstalk in Metastatic Breast Tumors
por: Mogol, Ayca, et al.
Publicado: (2022) -
THU558 Combination Therapy Of Acetyl-CoA Synthetase Inhibitor And Fulvestrant Reverse Epigenetic Alterations Of Metastatic Breast Cancer Cells And Reduce Cancer Cell Proliferation
por: Mogol, Ayca N, et al.
Publicado: (2023) -
THU501 Examining The Link Between Exposure To Neighborhood Violence And PRMT6 And Glucocorticoid Receptor Binding To Chromatin In Lung Tumors
por: Heath, Hannah, et al.
Publicado: (2023) -
THU500 Geospatial Analysis To Quantify Spatial Heterogeneity Of Tumor Microenvironment
por: Yoo, Jin Young, et al.
Publicado: (2023) -
THU486 Identification Of Metabolic And Molecular Mechanisms Driving Estrogen Receptor Positive Breast Cancer Disparities Using A Machine-Learning Pipeline
por: Casiano, Ashlie Santaliz, et al.
Publicado: (2023)